Switch from mepolizumab/benralizumab to depemokimab safe in severe asthma

ORLANDO — Both patients with asthma who switched from mepolizumab/benralizumab to depemokimab and patients who continued mepolizumab/benralizumab had low annualized exacerbation rates, according to results presented here. Depemokimab (Exdensur, GSK) is given twice a year since it is the first ultra-long-acting anti-IL-5 therapy, according to the presentation given at the American